ArticleNeurochemical research2026
Exploring the Anticonvulsant and Neuropreventive Effects of Ganoderma lucidum Extract in the Pentylenetetrazole-Kindling Model: Analysis of Cognitive Comorbidities Associated with Epilepsy.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential neuroprotective and anticonvulsant effects ofFrontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress associated with neuronal death resulting from excitotoxicity represents a key pathophysiological mechanism contributing to the genesis and progression of neurofunctional alterations in epilepsy. Here, we evaluated the neuroprotective properties of GLE (300 mg/kg; i.g.) in the PTZ-induced Kindling model. Four groups of male Wistar rats were randomly assigned: control, PTZ, GLE-300, and Diazepam, each consisting of 8 rats. During the kindling process, 11 injections of PTZ (35 mg/kg; i.p.) were given every 48 h (21 consecutive days) to create a model of epilepsy. The 5-stage Racine scale was used to assess the severity of seizures. Moris water maze, Y maze test and novel object recognition was used to determine cognitive comorbidities. An assessment of oxidative stress biomarkers in the hippocampus was performed. Histological evaluation was also performed to quantify neuronal death in CA1 and CA3 using nissl staining. Our results show that supplementing animals with GLE attenuates PTZ-induced cognitive impairment and improves memory and learning deficits. In addition, GLE attenuated seizure severity and oxidative stress by decreasing lipid peroxidation and nitric oxide levels, and increasing superoxide dismutase and catalase activities in the hippocampus. Histopathological analysis also confirmed these results. These results indicate that GLE supplementation has therapeutic impacts on cognitive comorbidities and decreases PTZ damage, which may be associated with reduced oxidative stress in the hippocampus.
Indexed as
Identifiers
41557102What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.